Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237261 | 0.88 | OPRD1 (0.56) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4822831 | 0.86 | OPRD1 (0.55) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4827770 | 0.86 | OPRD1 (0.63) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL1996254 | 0.84 | OPRD1 (0.60) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL12569804 | 0.83 | OPRD1 (0.72) | OPRD1OPRM1KCNH2 | |
| SCHEMBL12569805 | 0.83 | OPRD1 (0.72) | OPRD1OPRM1KCNH2 | |
| SCHEMBL2001487 | 0.83 | OPRD1 (0.72) | OPRD1OPRM1KCNH2 | |
| SCHEMBL4829690 | 0.82 | OPRD1 (0.74) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6245607 | 0.81 | OPRD1 (0.55) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6773667 | 0.77 | OPRD1 (0.69) | OPRD1OPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396834-B2 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-7396834-B2 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-7396834-B2 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-20060167004-A1 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167004-A1 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | TRPV1, OPRM1, OPRK1 | OPRD1 8/4885OPRM1 2/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.